Chelsea Therapeutics International Ltd.  

(Public, NASDAQ:CHTP)   Watch this stock  
Find more results for CHTP
4.85
-0.20 (-3.96%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.75 - 5.10
52 week 1.68 - 6.83
Open 5.08
Vol / Avg. 1.90M/3.01M
Mkt cap 380.40M
P/E     -
Div/yield     -
EPS -0.24
Shares 78.43M
Beta 1.82
Inst. own 38%
Jun 9, 2014
CHELSEA THERAPEUTICS Annual Shareholder Meeting (Estimated) Add to calendar
Apr 28, 2014
Q1 2014 CHELSEA THERAPEUTICS Earnings Release (Estimated) Add to calendar
Mar 11, 2014
Q4 2013 CHELSEA THERAPEUTICS Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -62.17% -43.53%
Return on average equity -68.35% -47.47%
Employees 19 -
CDP Score - -

Address

Suite 200, 3530 Toringdon Way
CHARLOTTE, NC 28277
United States - Map
+1-704-3411516 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson�s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension (IDH), fibromyalgia, adult attention deficit hyperactivity disorder (ADHD), chronic fatigue syndrome (CFS), freezing of gait in PD and Down syndrome. In addition, the Company is developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis and is exploring potential applications in multiple other autoimmune disorders.

Officers and directors

Michael Weiser M.D., Ph.D. Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Joseph G. Oliveto President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
J. Nick Riehle Chief Financial Officer, Vice President - Administration
Age: 60
Bio & Compensation  - Reuters
L. Arthur Hewitt Ph.D. Chief Scientific Officer, Vice President
Age: 59
Bio & Compensation  - Reuters
William D. Schwieterman M.D. Chief Medical Officer, Vice President
Age: 55
Bio & Compensation  - Reuters
Michael J. Roberts Ph.D. Vice President - Business Development
Age: 43
Bio & Compensation  - Reuters
Keith W. Schmidt Chief Commercial Officer
Age: 63
Bio & Compensation  - Reuters
Kevan Clemens Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
William Dodge Rueckert Independent Director
Age: 60
Bio & Compensation  - Reuters
Roger G. Stoll Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters